News

Published on 22 Oct 2024 on Forbes

SAP BrandVoice: Drug Shortages Create Surprising Opportunity For Pharma Supply...


Article preview image

Global drug shortages underscore the pharmaceutical industry's reliance on fragile supply chains,...

NASDAQ.GILD price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
SAP BrandVoice: Drug Shortages Create Surprising Opportunity For Pharma Supply...

Global drug shortages underscore the pharmaceutical industry's reliance on fragile supply chains,...

Forbes 22 Oct 2024

Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows...

On Saturday, Gilead Sciences, Inc. (NASDAQ:GILD) and Merck & Co. Inc. (NYSE:MRK) revealed new...

Benzinga · via Yahoo Finance 21 Oct 2024

Goldman Sachs: Gilead Sciences, Inc. (NASDAQ:GILD) Is A Stock With High...

We recently looked at Goldman Sachs’ Stocks With Highest Consensus Returns: 42 Stocks With The...

Insider Monkey · via Yahoo Finance 19 Oct 2024

Gilead voluntarily withdraws urothelial cancer drug in US

Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in...

Reuters 18 Oct 2024

After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of...

On Friday, Gilead Sciences, Inc. (NASDAQ:GILD) announced plans to voluntarily withdraw the U.S....

Benzinga · via Yahoo Finance 18 Oct 2024

Is Gilead Sciences, Inc. (NASDAQ:GILD) The Most Popular Stock Among Mutual Funds...

We recently made a list of Goldman Sachs’ List Of Stocks Popular With Mutual Fund Managers: Top 2...

Insider Monkey · via Yahoo Finance 8 Oct 2024

Gilead's Trodelvy fails bladder cancer trial, modestly extends lung cancer survival

, opens new tab Trodelvy failed to improve survival for patients with advanced bladder cancer and...

Reuters 31 May 2024

Gilead drug fails to confirm its FDA approval in bladder cancer - Silicon Valley Business Journal

A drug at the center of a $21 billion acquisition by Gilead Sciences Inc. four years ago failed a...

The Business Journals 31 May 2024

Gilead's Trodelvy Fails To Hit Primary Goal In Late-Stage Study With Most Common Type Of Bladder...

On Thursday, Gilead Sciences Inc GILD announced topline results from the confirmatory Phase 3 TRO...

Benzinga 31 May 2024

Gilead's (GILD) Urothelial Cancer Study Did Not Meet Its Primary Goal

Gilead Sciences, Inc. GILD announced the failure of its late-stage confirmatory TROPiCS-04 study ...

Zacks via Yahoo Finance 31 May 2024